The CorPath 200 System included in this year's scientific symposia: Novel Therapies and the "Best" New Device Concepts for 2012; Leading interventional cardiologists to present robotic-PCI adoption in the Cath Lab
NATICK, Mass. – October 18, 2012 – Corindus Vascular Robotics, a developer of precision vascular robotics, today announced leading experts in interventional cardiology will speak about their clinical experience using the CorPath® 200 System at this year's Transcatheter Cardiovascular Therapeutics' annual meeting, TCT2012.
As part of TCT's scientific symposia "Interventional Innovation: Novel Therapies and the "Best" New Device Concepts for 2012," Giora Weisz, M.D., director of Clinical Research at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and associate professor of Medicine at Columbia University College of Physicians and Surgeons, New York will present a taped case and discussion titled "The Corindus Robotic-Assisted Coronary Angioplasty System."
"Robotic-assisted PCI's will revolutionize the way interventional cardiologists perform the procedure," said Dr. Weisz. "The case presentation will highlight my clinical use of the CorPath 200 System and how—in my experience—robotic-assisted PCI is safe and provides enhanced precision and control of the guidewire, balloon and stent. Additionally, sitting comfortably during the procedure, without the need for a lead apron and in proximity to the monitors, allows me to improve visualization of the treatment targets. Improved measurement and visualization is important as 10-20 percent of patients require a second stent due to inaccurate placement or size of the first stent."
Additionally, Corindus Vascular Robotics and Philips Healthcare will co-sponsor a symposium, "Introducing Robotic-Assisted PCI into Your Cath Lab Practice." The event will take place on Thursday, October 25 at 7:00 a.m. EDT at the Miami Beach Convention Center. Moderated by Peter J. Fitzgerald, M.D., Stanford University and Dr. Weisz, the symposium will include presentations on the benefits of robotic-assisted percutaneous coronary intervention (PCI) procedures, followed by roundtable discussion. Presentations include:
"Receiving FDA clearance earlier this year for the CorPath 200 System, TCT2012 marks an exciting opportunity to educate interventional cardiologists not only about the benefits of the CorPath 200 System, but its use in clinical practice," said David Handler, CEO of Corindus Vascular Robotics. "Several leading medical centers have already adopted the CorPath 200 System to enhance their hospital'scardiology programs. The adoption and excitement for the technology further solidifies our belief that the CorPath will change standard of care, and improve safety and the quality of care in the cath lab."
To learn more about Corindus Vascular Robotics or to book a hands-on demonstration of the CorPath 200 System at Corindus' booth (exhibit hall booth 215) at TCT2012, please call 508.653.3335 x200 or email TCT2012@corindus.com.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: